stockrow
Saturday 7 November 2026
Export DNA’s income statement to Excel — free account
Ginkgo Bioworks Holdings, Inc.
Ginkgo Bioworks Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $170.2 million, down 25.1% from fiscal 2024.
- Revenue
- −59.4%
- EPS
- +31.8%
- Free cash flow
- −16.4%
Quarter to June 2026, against a year earlier
11.19
1.23
+12.35%
Follow DNA
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | 5 | 4 | 3 | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Altman Z-Score |
(7.61) | (6.22) | (1.94) | (2.38) | 10.07 | — | — | — |
P/S ratio |
2.71 | 2.24 | 12.91 | 5.55 | 36.01 | 0.00 | 0.00 | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Altman Z″-Score (non-manufacturers) |
(16.72) | (13.05) | (8.52) | (5.92) | (1.25) | 2.22 | — | — |
P/Operating CF |
(9.67) | (12.01) | (56.15) | (25.38) | (68.26) | (271.29) | (271.29) | — |
Beneish M-Score |
(2.80) | (2.72) | (5.42) | (5.05) | (3.50) | — | — | — |
P/B ratio |
0.91 | 0.71 | 2.96 | 1.53 | 7.21 | 2,611.53 | 2,611.53 | — |
Price to Tangible BV |
1.01 | 0.79 | 3.36 | 1.70 | 7.41 | 0.00 | 0.00 | — |
EV/Sales |
0.58 | 0.03 | 9.40 | 2.92 | 31.14 | 0.00 | 0.00 | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
EV/Operating CF |
(0.57) | (0.02) | (8.00) | (5.54) | (38.50) | (140.87) | (140.87) | — |
EV/FCF |
(0.55) | (0.02) | (7.12) | (4.59) | (31.49) | (95.45) | (95.45) | — |
Quick Ratio |
4.66 | 5.44 | 5.87 | 8.08 | 12.51 | 5.50 | — | — |
Current Ratio |
4.92 | 5.62 | 6.11 | 8.38 | 12.79 | 5.83 | — | — |
Net Debt/EBITDA |
1.63 | 1.25 | 1.19 | 0.61 | 0.85 | 2.96 | 0.00 | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 1.08% | 2.45% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.04 | 0.00 | — |
Asset Turnover |
0.14 | 0.15 | 0.12 | 0.21 | 0.23 | 0.23 | 0.00 | — |
Operating CF/Net income |
0.55 | 0.58 | 0.33 | 0.12 | 0.14 | 1.07 | 0.37 | — |
Capex/Depreciation |
(0.13) | (0.56) | (0.52) | (1.23) | (1.94) | (4.17) | (2.07) | — |
Interest Coverage |
— | (5,954.86) | (9,294.69) | (20,839.17) | (770.53) | (57.45) | (29.57) | — |
| (51.08%) | (60.34%) | (63.02%) | (127.43%) | (179.64%) | (12.88%) | 0.00% | — | |
| (25.05%) | (35.96%) | (42.47%) | (91.31%) | (133.28%) | (37.51%) | 0.00% | — | |
ROIC |
(229.21%) | (226.46%) | (352.92%) | (328.33%) | (2,881.62%) | (80.97%) | 0.00% | — |
Return on Tangible Assets |
(57.53%) | (78.24%) | (87.02%) | (132.23%) | (105.54%) | (26.67%) | 0.00% | — |
Average Days of Receivables |
52.03 | 36.08 | 25.98 | 63.01 | 158.34 | 104.30 | 0.00 | — |
Research and Development Expense of Revenue |
143.27% | 186.78% | 230.90% | 220.35% | 366.32% | 208.42% | 177.73% | — |
Selling, General and Administrative Expense of Revenue |
107.72% | 108.42% | 153.12% | 299.31% | 274.97% | 49.97% | 54.41% | — |
Intangible Assets out of Total Assets |
0.05 | 0.05 | 0.08 | 0.07 | 0.02 | 0.01 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
47.92% | 49.48% | 91.42% | 404.15% | 511.74% | 0.62% | 1.42% | — |
Graham Net Nets |
(0.30) | (0.12) | 0.13 | 0.24 | 0.11 | (0.13) | (0.13) | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Earnings Yield |
(67.99%) | (108.76%) | (28.14%) | (81.01%) | (14.80%) | (1.73%) | (1.73%) | — |
Free Cash Flow Yield |
(38.66%) | (74.86%) | (10.22%) | (11.48%) | (2.75%) | (1.05%) | (1.05%) | — |
Revenue per Share |
3.07 | 4.38 | 5.17 | 11.38 | 9.23 | 2.41 | 1.89 | — |
Operating CF per Share |
(3.08) | (6.16) | (6.08) | (6.01) | (7.47) | (4.26) | (1.55) | — |
Capex per Share |
(0.13) | (1.19) | (0.75) | (1.25) | (1.66) | (1.81) | (0.77) | — |
Free Cash Flow per Share |
(3.21) | (7.35) | (6.83) | (7.25) | (9.13) | (6.08) | (2.33) | — |
Cash per Share |
7.62 | 10.82 | 19.42 | 31.35 | 45.59 | 11.95 | 0.00 | — |
Shareholders Equity per Share |
9.17 | 13.80 | 22.57 | 41.36 | 46.10 | 14.75 | 0.00 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
9.17 | 13.80 | 22.57 | 41.36 | 46.10 | 14.75 | 0.00 | — |
Free Cash Flow |
(178.15) | (381.48) | (331.87) | (304.47) | (310.34) | (193.65) | (66.88) | — |
Working Capital |
375.87 | 495.48 | 837.89 | 1,277.12 | 1,588.28 | 353.32 | — | — |
Capital Expenditures |
(7.09) | (61.89) | (36.37) | (52.27) | (56.52) | (57.82) | (22.22) | — |
Net Current Asset Value |
(139.27) | (58.65) | 433.56 | 647.04 | 1,219.43 | 221.44 | 0.00 | — |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Capex to Sales |
0.04 | 0.27 | 0.14 | 0.11 | 0.18 | 0.75 | 0.41 | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Other line items | ||||||||
Depreciation/Fixed assets |
0.33 | 0.54 | 0.37 | 0.14 | 0.20 | 0.11 | 0.00 | — |
Cash ROIC |
(19.13%) | (29.86%) | (16.26%) | (9.98%) | (9.88%) | (22.33%) | 0.00% | — |
Accounts Receivable Turnover |
7.29 | 11.26 | 5.01 | 4.37 | 3.97 | 0.88 | 0.00 | — |
Accounts Payable Turnover |
3.80 | 3.79 | 5.46 | 21.91 | 11.75 | 1.42 | — | — |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 52.86 | 42.54 | 5.20 | — | — |
Average Days of Payables |
82.10 | 116.09 | 63.01 | 18.68 | 23.05 | 324.83 | — | — |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 9.46 | 63.97 | — | — |
Average Receivables |
23.35 | 20.17 | 50.18 | 109.30 | 79.02 | 87.50 | — | — |
Average Payables |
12.37 | 11.75 | 9.89 | 9.32 | 11.04 | 11.00 | — | — |
Average Inventory |
— | — | — | 3.86 | 3.05 | 3.00 | — | — |
Average Assets |
1,248.57 | 1,521.40 | 2,102.33 | 2,305.16 | 1,373.07 | 337.58 | 0.00 | — |
Average Common Equity |
612.32 | 906.60 | 1,416.71 | 1,651.83 | 1,018.72 | 983.00 | — | — |
Columns are period end dates · fundamentals updated 26 Oct 2026